SCHEMBL14358641

SCHEMBL14358641

CN(C)c1ccc(C=Cc2ccc(NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
NR3C2 P08235 2/20 0.56
RELA Q04206 1/20 0.52
APP P05067 4/20 0.50
PTGS1 P23219 1/20 0.50
MAPT P10636 4/20 0.49
ALDH1A1 P00352 4/20 0.49
LMNA P02545 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
GFER P55789 2/20 0.49
MAPK1 P28482 1/20 0.49
MCL1 Q07820 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
CASP1 P29466 2/20 0.49
HBB P68871 2/20 0.49
NPC1 O15118 1/20 0.49
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14358638 1.00 CA1 (0.56) CA1CA2NR3C2RELAAPP
SCHEMBL10926948 0.89 CA1 (0.68) CA1CA2NR3C2MAPTALDH1A1
SCHEMBL14358816 0.87 KEAP1 (0.58) CA1CA2NR3C2MAPTALDH1A1
SCHEMBL14358814 0.87 KEAP1 (0.58) CA1CA2NR3C2MAPTALDH1A1
SCHEMBL14359437 0.86 HPGD (0.58) CA1CA2RELAAPPPTGS1
SCHEMBL14358646 0.82 CA1 (0.51) CA1CA2RELAAPPPTGS1
SCHEMBL14358644 0.82 CA1 (0.51) CA1CA2RELAAPPPTGS1
SCHEMBL15218448 0.80 KEAP1 (0.67) CA1CA2NR3C2ALDH1A1LMNA
SCHEMBL14358482 0.80 CA1 (0.49) CA1CA2RELAAPPPTGS1
SCHEMBL28812414 0.80 CA1 (0.49) CA1CA2RELAAPPPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP claimed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US claimed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO claimed
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (US) 2019-02-19 US disclosed
EP-2724156-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE JACKSON LAB (US) 2017-08-16 EP disclosed
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP disclosed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US disclosed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE BAK1, SSB, MRE11 CA1 1037/4885CA2 1910/4885NR3C2 4473/4885
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease BAK1, SSB, MRE11 CA1 1037/4885CA2 1910/4885NR3C2 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.